BioVersys announces a €6.92m funding of its TRIC-TB project by IMI2 JU
BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No853800. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The project previously received valuable financial support from the Wellcome Trust. TRIC-TB is one of BioVersys’ leading pipeline assets directed at tuberculosis (TB), based on BioVersys’ award winning Transcriptional Regulatory Inhibitory Compounds (TRICs) Platform which reaches a significant new milestone with the selection of two pre-clinical candidates and validation through the support of the IMI2 JUand the extension of the R&D collaboration with GSK. The funding provided by the IMI2 JU under the AntiMicrobial Resistance (AMR) Accelerator Program will allow for this unique Global Health project to continue its progress through IND enabling studies and into First in Human studies by early 2020.